Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

At-Home brain zaps show promise for depression relief

NCT ID NCT07228468

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a safe, non-invasive brain stimulation treatment called tDCS that people can use at home to ease depression. About 438 adults with major depression will either receive active tDCS plus their usual care, or just usual care alone. The goal is to see if adding tDCS reduces depressive symptoms more than standard treatment alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 438 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Adults aged 18 years or over 2. Current episode of depression based on Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria (APA, 2013) for major depressive disorder (MDD) as assessed by structured clinical assessment, Mini-International Neuropsychiatric Interview (MINI) (Sheehan et al., 1998) 3. Having at least a moderate severity of depressive symptoms as measured by a score of at least 18 in MADRS 4. Either not taking antidepressant medication or taking a stable dose of antidepressant medication for at least 6 weeks before enrolment. 5. Either not currently in psychotherapy or in ongoing psychotherapy for at least 6 weeks before enrolment. 6. Being under the care of GP 7. Agreeable for GP to be regularly informed about study participation 8. Able to provide written, informed consent Exclusion Criteria: 1. Significant suicide risk as measured by answering 'yes' to questions 4, 5 or 6 on the Columbia Suicide Severity Rating Scale (C-SSRS) Screen (Posner et al., 2011) 2. Primary comorbid psychiatric disorder (e.g. obsessive compulsive disorder) based on DSM-5 criteria as assessed in MINI 3. Current daily use of medications that affect cortical excitability (e.g. benzodiazepines) 4. Current illicit drug use or heavy alcohol use with high risk of alcohol use disorder as measured by a score of 8 or more in Alcohol use disorders identification test consumption (AUDIT C) (Khadjesari et al., 2017; NICE, 2023) 5. History of electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), cranial electrotherapy stimulation (CES), transcranial direct current stimulation (tDCS), deep brain stimulation (DBS), or other brain stimulation 6. History of esketamine / ketamine for treatment of depression 7. History of psychosurgery for depression 8. Having cognitive impairment (e.g. dementia) 9. Current medical disorder or neurological disorder that may mimic mood disorder (e.g. hormonal disorder, unstable heart disease) 10. Have any implant in the brain or neurocranial defect 11. Have shrapnel or any ferromagnetic material in the head 12. Have any active implantable medical device (e.g. pacemaker) 13. If female and of child-bearing potential, currently pregnant or planning to become pregnant during the study 14. Concurrent enrolment in another interventional study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Major depressive disorder (MDD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cardiff and Vale Health Board

    NOT_YET_RECRUITING

    Cardiff, CF24 4HQ, United Kingdom

  • Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust

    NOT_YET_RECRUITING

    Newcastle, NE4 5PL, United Kingdom

  • Hampshire and Isle of Wight Healthcare NHS Foundation Trust

    NOT_YET_RECRUITING

    Southampton, SO14 3DT, United Kingdom

  • Northamptonshire Healthcare NHS Foundation Trust

    NOT_YET_RECRUITING

    Northampton, NN5 6UD, United Kingdom

  • Nottinghamshire Healthcare NHS Foundation Trust

    NOT_YET_RECRUITING

    Nottingham, NG7 2UH, United Kingdom

  • South London and Maudsley NHS Foundation Trust

    RECRUITING

    London, SE5 8AF, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.